ангиотензин II 治疗与 ARDS 患者的氧化改善有关,这些患者患有耐火性血管扩张性休克
Daniel E Leisman1,2, Damian R Handisides3, Lakhmir S Chawla4
1Department of Medicine, Massachusetts General Hospital, 55 Fruit St., GRB 7-730, Boston, MA, 02114, USA. dleisman@mgh.harvard.edu.
Annals of intensive care
|December 16, 2023
概括
ангиотензин-II 治疗改善了急性呼吸窘迫综合征 (ARDS) 和血管扩张性休克患者的氧化. 这一发现表明,血管素II在ARDS治疗中可能发挥治疗作用.
科学领域:
- 关键护理医学 关键护理医学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在急性呼吸窘迫综合征 (ARDS) 中,氨酸-血管酶系统调节的作用尚不清楚,并且缺乏随机试验数据.
- 之前的研究还没有研究血管素II在ARDS中的生理作用.
- 这项研究旨在评估血管素II是否能改善与冲击相关的ARDS中的氧化.
研究的目的:
- 确定血管素-II在改善ARDS和血管扩张性休克患者的氧化功效.
- 评估 ангиотензин-II 对各种呼吸道和血液动力学参数的影响.
- 评估 ангиотензин-II 对临床结果,如无呼吸器日和死亡率的影响.
主要方法:
- 进行了对高输出冲击 (ATHOS-3) 的 ангиотензин疗法试验的后期小组分析.
- 包括符合修改的柏林ARDS标准的患者.
- 主要结局是48小时后PaO2/FiO2比率 (P:F) 的变化,调整为基线P:F.
主要成果:
- 与安慰剂相比, ангиотензин-II 治疗导致P:F比率显著增加 (98.4 mmHg 差异,p=0.0028).
- 氧化指数也得到改善,与安吉奥素II,显示显著下降与安慰剂相比 (-4.8cmH2O/mmHg,p=0.0273).
- 接受 angiotensin-II 的患者中,更高比例的患者实现了持续的血液动力学反应 (64.7%与36.2%相比),并且有改善生存率和无呼吸器日的趋势.
结论:
- ангиотензин-II 给药与ARDS 患者和catecholamine-refractory 血管扩张性休克患者的氧化改善有关.
- 这些结果为进一步研究血管增生素-II作为ARDS治疗在血管扩张性休克的背景下提供了生理基础.
- 这项研究支持将宁-血管酶系统作为针对复杂危急疾病管理的潜在目标.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Antihypertensive Drugs: Angiotensin II Receptor Blockers
743
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
743
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
225
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
225
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
648
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
648
Antihypertensive Drugs: Direct Renin Inhibitors
632
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
632


